Thomas J. Oxley is a brain-computer interface specialist and the founder and CEO of Synchron, a neural interface technology company.
At Synchron, Thomas J. Oxley is developing an endovascular, implantable brain-computer interface, Stentrode, which aims to provide treatment for patients with debilitating illnesses. The device can record brain activity from within a blood vessel and allow a patient’s thoughts to be transmitted wirelessly through the skin to control an array of digital devices.
Oxley completed his PhD in neural engineering at the University of Melbourne. He completed an endovascular neurosurgery fellowship at Mount Sinai Hospital in New York. He has performed more than 1,600 endovascular neurosurgical procedures and has published more than 100 internationally peer reviewed articles in journals including Nature Biotechnology, Nature Biomedical Engineering, New England Journal of Medicine and The Lancet.